TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Physical Activity in Adults With Amputation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria (all participants):~* Ages 18-60 years~* Able to read and speak English~* Saltin-Grimby Physical Activity Level of I or II~Inclusion Criteria (individuals with unilateral, transtibial amputations):~* Unilateral, transtibial (below-the-knee) amputation~* Currently wearing a prosthesis with use of an assistive device no greater than a cane~* Wearing prosthetic at least 8 hours per day and inside and outside the home: This criteria will help to ensure that adults are beyond the initial weaning into a prosthetic period and are prosthetic users rather than nonusers.~Inclusion Criteria (controls):~* Pain-free in the legs and low back regions~* Able to walk without an assistive device~Exclusion Criteria:~* Current infections or illnesses that would affect safe participation in the study~* Past medical history of significant cardiovascular disease (e.g. congestive heart failure or previous heart attacks), significant neurological disease (e.g. Parkinson's, Multiple Sclerosis) significant neurological event (e.g. stroke), or major lung condition (e.g. Chronic obstructive pulmonary disease, emphysema)~* Uncontrolled high blood pressure~* Uncontrolled Diabetes Mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Unilateral Transtibial Amputation (Type: None): Individuals with a unilateral, transtibial amputation.
- Controls (Type: None): Healthy adults without a lower-limb amputation who have been matched to participants in the Unilateral Transtibial Amputation group based on age, sex, and body mass index.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Nighttime Dialysis on the Inflammation of Kidney Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Men and women at least age 18 who receive hemodialysis three times a week for at least 3 months and meet the criteria for home instruction in nocturnal dialysis -~Exclusion Criteria:~No diabetes, any unstable clinical condition, chronic infection (including hepatitis, HIV), endocrine disorders or serious digestive problems, lipid-lowering medication , LDL cholesterol \<190 mg/dL and triglycerides less than 600 mg/dL, body mass index \<35, blood pressure \<160/100, hemoglobin \>10.0, no cholesterol-lowering medicine, able to change from Renagel (has lipid effects) to Phoslo for the duration of the study, cigarette smoking no more than half a pack per day

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Angioplasty of the Tibial Arteries Augmented Radio Frequency Denervation of the Popliteal Artery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic lower limb ischemia 3-6 degree by Rutherford;~* Stenosis or occlusion of no more than 2 tibial arteries;~* Stenosis of the tibial arteries more than 70 %;~* Duration stenosis or occlusion no more than 70 mm;~Exclusion Criteria:~* Diabetes mellitus type 2~* Occlusion or stenosis of all tibial arteries~* Expressed calcification of tibial arteries angioplasty tolerant~* Hemodynamically significant stenosis of the popliteal artery;~* Chronic heart failure of III-IV functional class by NYHA classification;~* Decompensated chronic pulmonary heart;~* Severe hepatic or renal failure (bilirubin\> 35 mmol / l, glomerular filtration rate \<60 mL / min);~* Polyvalent drug allergy;~* Cancer in the terminal stage with a life expectancy less than 6 months;~* Patient refusal to participate or continue to participate in the study;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- angioplasty tibial arteries (Type: ACTIVE_COMPARATOR): None
- radio frequency denervation popliteal artery by the use (Type: EXPERIMENTAL): radio frequency denervation popliteal artery Vessix Renal Denervation System Balloon

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Immune Response to Seasonal FluMist in Healthy Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Medically eligible healthy men and women between the ages of 20 to 49 years old.~Exclusion Criteria:~* A medical condition that places them at high risk for complications from influenza, including those with chronic heart or lung disease, such as asthma or reactive airway disease; people with medical conditions such as diabetes or kidney failure; or people with illnesses that weaken the immune system, or who take medications that can weaken the immune system.~* A history of Guillain-Barré Syndrome that occurred after receiving influenza vaccine~* Currently pregnant~* Have a severe allergy to chicken eggs or who are allergic to any of the nasal spray vaccine components~* Have had flu within the current flu season.~* Have had a flu vaccine within the current flu season.~* Have close contact with someone whose immune system is so weak they require care in a protected environment (such as bone marrow transplant unit).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Live Attenuated Influenza Vaccine (Type: EXPERIMENTAL): Single intervention study- all participants will receive LAIV instead of injectable flu vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Rapid Throughput Screening for Human COVID-19 Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult males and females age 18 or greater.~* Undergoing COVID-19 testing by PCR.~* Willing and able to provide informed consent.~* Pregnant females (minimal risk study, no risk from ECG).~Exclusion Criteria:~- Unwilling or unable to provide informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of OCD~* Engaging in reassurance seeking more than once a day about the same thing~* Willingness to allow the experimenter to contact a significant other from whom the participant seeks reassurance regularly~* Ability to read, write, and communicate in English~Exclusion Criteria:~* Current suicidal ideation/intent~* Current substance abuse~* Psychosis~* Diagnosis of bipolar disorder (I or II)~* If participants are on medication they must be on a stable dose (i.e., have maintained a consistent dose for at least three months) and agree not to change their medication regimen for the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Support-seeking intervention (Type: EXPERIMENTAL): Cognitive-behavioural therapy intervention that guides participants to seek support rather than reassurance; participants' significant others are asked to provide support rather than reassurance.
- Family accommodation reduction intervention (Type: ACTIVE_COMPARATOR): Cognitive-behavioural therapy intervention that guides participants' significant others to withhold reassurance when it is requested; participants are asked to refrain from seeking reassurance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have carcinoma of the uterine cervix.~* Patients with squamous cell, adenocarcinoma, and adenosquamous carcinoma are eligible.~* International Federation of Gynecology and Obstetrics (FIGO) Stage I to IVA~* Patients must have no evidence of metastatic disease outside of the pelvis (except to the para-aortic nodes), by PET.~* Patients must have a Karnofsky Performance Status of \>= 60 and no medical contraindications to the administration of chemotherapy.~* Age \>= 18.~* Adequate bone marrow function: white blood cells (WBC) \>= 4000/mm3, platelets \>= 100,000 mm3.~* Adequate renal function: BUN \<= 25 mg/dl, creatinine \<= 1.2 mg/dl (urinary diversion is permitted to improve renal function).~* Patients must have bilirubin \<= 1.5 mg/dl.~* Signed study-specific informed consent.~Exclusion Criteria:~* No positive lymph nodes by FDG PET~* Positive supraclavicular lymph nodes by FDG PET Scan or evidence of more distant disease.~* FIGO Stage IVB+ Cervical Cancer~* No prior (within 5 years) or simultaneous malignancies (other than cutaneous basal cell carcinoma).~* Karnofsky Performance Status \<60.~* Patients with significant medical illness preventing the use of full dose chemotherapy are excluded.~* Patients with the following histologies are excluded: small cell, carcinoid, glassy cell, clear cell and adenoid cystic.~* Life expectancy \< 6 months.~* Patients with poorly controlled diabetes mellitus (fasting blood glucose level \> 200 mg/dL) are not eligible.~* No prior surgery for treatment of disease other than exploratory laparotomy or biopsy.~* No previous systemic chemotherapy.~* No pelvic radiation therapy is permitted other than transvaginal irradiation to control bleeding.~* Pregnant women are ineligible and those of child-bearing potential should practice contraception.~* Patients with abnormal liver function tests

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group 1 (Type: EXPERIMENTAL): Pelvic Lymph Nodes Only Positive on FDG PET.~IMRT External Beam radiation to the para-aortic region (45 Gy)~Pelvis intracavitary brachytherapy (6 HDR treatments)~Weekly cisplatin 40 mg/m\^2
- Treatment Group 2 (Type: EXPERIMENTAL): Para-Aortic Lymph Nodes Positive on FDG PET~IMRT (50.4 Gy to para-aortic lymph node bed with a 10.8 Gy boost to nodes)~IMRT external beam pelvic radiation therapy as appropriate for stage~Intracavitary brachytherapy (6 HDR treatments)~Weekly cisplatin (40 mg/m\^2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
1. Written informed consent~2. Physician requested salvage (defined as refractory to first, requirement for second line or greater) treatment for ADV and / or CMV reactivation post allogeneic HSCT.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Single Ascending Dose Trial of CVL-936 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 14.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male subjects and female subjects of nonchildbearing potential, ages 18 to 50 years~Exclusion Criteria:~1. Subjects with a current history of significant pulmonary, gastrointestinal, renal, hepatic, metabolic, endocrine, hematological, immunological, psychiatric, or neurological disease that, in the opinion of the investigator or medical monitor, could compromise either subject safety or the results of the trial.~2. Subjects with epilepsy or a history of seizures~3. Systolic supine blood pressure ≥130 mmHg and/or supine diastolic blood pressure ≥80 mmHg at Screening or Day -1, or orthostatic hypotension at Screening or Day -1.~4. Subjects with a history of hypersensitivity to any dopamine-blocker medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Active Comparator: Group 1 Period 1: 0.5mg CVL-936 (Type: ACTIVE_COMPARATOR): Oral suspension/solution
- Placebo Comparator: Group 1 Period 1: 0.5mg Matching Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo; Oral suspension/solution
- Active Comparator: Group 1 Period 2:TBD mg CVL-936 (Type: ACTIVE_COMPARATOR): Oral suspension/solution
- Placebo Comparator: Group 1 Period 2:TBD mg Matching Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo; Oral suspension/solution
- Active Comparator: Group 1 Period 3:TBD mg CVL-936 (Type: ACTIVE_COMPARATOR): Oral suspension/solution
- Placebo Comparator: Group 1 Period 3:TBD mg Matching Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo; Oral suspension/solution
- Active Comparator: Group 2 Period 1:TBD mg CVL-936 (Type: ACTIVE_COMPARATOR): Oral suspension/solution
- Placebo Comparator: Group 2 Period 1:TBD mg Matching Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo; Oral suspension/solution
- Active Comparator: Group 2 Period 2:TBD mg CVL-936 (Type: ACTIVE_COMPARATOR): Oral suspension/solution
- Placebo Comparator: Group 2 Period 2:TBD mg Matching Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo; Oral suspension/solution
- Active Comparator: Group 2 Period 3:TBD mg CVL-936 (Type: ACTIVE_COMPARATOR): Oral suspension/solution
- Placebo Comparator: Group 2 Period 3:TBD mg Matching Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo; Oral suspension/solution
- Active Comparator: Group 3: TBD mg CVL-936 (Type: ACTIVE_COMPARATOR): Oral suspension/solution
- Placebo Comparator: Group 3: TBD mg Matching Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo; Oral suspension/solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: TPI Medication Comparison - Ketorolac, Lidocaine, or Dexamethasone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Men or women age 18 or over~2. At least one active trigger point~Exclusion Criteria:~1. Allergy or contraindication to any NSAID, CS, or local anesthetic~2. Receiving anticoagulant medication~3. History of bleeding disorder~4. Pregnant or breast feeding women~5. Gastrointestinal ulceration~6. Pre-existing renal disease~7. Pre-existing congestive heart failure~8. Diabetes mellitus~9. Prior myocardial infarction or stroke~10. Fibromyalgia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Ketorolac (Type: EXPERIMENTAL): Participants may be randomized to receive Ketorolac for their TPI.
- Lidocaine (Type: EXPERIMENTAL): Participants may be randomized to receive Lidocaine for their TPI.
- Dexamethasone (Type: EXPERIMENTAL): Participants may be randomized to receive Dexamethasone for their TPI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Strategy of Crossing Two Ablation Techniques (Cryoballoon and Radiofrequency) After the Recurrence of Paroxysmal AF and the Need for a New Procedure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Paroxysmal FA (one that ends, spontaneously or not, within 7 days of its onset. GUIDELINES ESC FA 2020)~* Have undergone an initial AF ablation procedure using Cryoballoon or point-to-point focal RF within the three years prior to the initial visit.~* During the initial AF ablation procedure ONLY pulmonary vein isolation / ablation will have been performed~* Documented recurrence of AF lasting more than 30 seconds after the first ablation procedure.~* With the ability and willingness to sign the informed consent of the patient.~* With a minimum follow-up capacity of 12 months.~Exclusion Criteria:~* Patients aged \<18 years.~* Previous heart surgery.~* Moderate or severe mitral valve disease.~* Severe dilation of the left atrium, defined as a volume greater than 48 ml / m2 or a left atrial diameter greater than 50 mm in the parasternal long axis.~* Contraindication for anticoagulation.~* Pregnancy or pregnancy intention during the 12-month follow-up.~* Life expectancy less than 12 months.~* Unavailability for follow-up for 12 months.~* Simultaneous participation in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cross-over of ablation technique (Type: EXPERIMENTAL): Cross-over of cardiac ablation procedures (cryotherapy and radiofrequency; radiofrequency and cryotherapy)
- Repetition of the same technique (Type: NO_INTERVENTION): Repeat the same procedure (cryotherapy and cryotherapy; radiofrequency and radiofrequency)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Cytologic or pathologic diagnosis consistent with ovarian carcinoma. Scheduled to undergo surgical evaluation. Karnofsky performance status of \> 60%.~Adequate organ function as defined by:~* Absolute neutrophil count (ANC) \> 1.5 x 10\^9/L~* Platelet count \> 100 x 10\^9/L~* Bilirubin \< 2.0 mg/dL~* Aspartate aminotransferase (AST) and Alanine transaminase (ALT) \< 2.5 X upper limit of normal~* Serum creatinine \< 2.0 mg/dL~* Forced expiratory volume at one second (FEV1) and forced vital capacity (FVC)\> 70% of predicted~* Left Ventricular Ejection Fraction \>50%~Recovered from the toxicity of any prior therapy. No evidence of active infection which requires antibiotic therapy. \> 18 years of age. Able to sign written informed consent.~Exclusion Criteria~Any significant intercurrent medical problems which may limit the amount of antibody they can tolerate, or render them ineligible for surgery.~Clinically significant cardiac disease (New York Heart Association Class III/IV, or abnormalities on ECG that are considered by the investigator to place the patient at increased risk), severe debilitating pulmonary disease, active infections or coagulation disorders.~Survival expectancy less than 12 weeks. History of autoimmune hepatitis or history of autoimmune disease. Chemotherapy, radiotherapy, or immunotherapy within four weeks prior to receiving hu3S193.~Psychiatric, addictive or other disorders that compromise the ability to give informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intraperitoneal (IP) Infusion of 111In-hu3S193 (Type: EXPERIMENTAL): Hu3S193 was administered intraperitoneally at a dose of 5 mg radiolabeled with 5 millicurie (mCi) of 111In.~Patients received 10 mCi 99mTc-sulphur colloid IP administered in 500 ml of normal saline to assure the absence of any loculation or heterogeneous distribution of radioactivity in the peritoneal cavity. A paracentesis catheter was inserted and the hu3S193 was diluted in 100 mL of 5% human serum albumin and administered as a continuous intraperitoneal infusion over 30 minutes. This was followed immediately by 900 mL of normal saline.
- Intravenous Infusion of 111In-hu3S193 (Type: EXPERIMENTAL): Hu3S193 was to be administered intravenously at a dose of 5 mg radiolabeled with 5 millicurie (mCi) of 111In, diluted in 100 mL of 5% human serum albumin and administered over a 30 minute period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues